Skip to main content

Greenberg Traurig Shareholders to Serve as Workshop Panelists for Therapeutic Area Partnerships 2014 Conference

BOSTON — Nov. 18, 2014 — Shareholders Wayne Elowe and David J. Dykeman from the international law firm Greenberg Traurig LLP are scheduled to co-lead, along with representatives from Catenion Management Consulting and Taylor Wessing Munich, at a pre-conference workshop titled “From Project Strategy to Exit Deals in Biotech” during the Therapeutic Area Partnerships (TAP) 2014 Conference taking place November 19-21, 2014 at the Hyatt Regency in Boston.

Elowe and Dykeman will speak Wednesday, November 19 between 2:30-5:30 p.m. The workshop will provide a comprehensive framework for the deal-making process in the biotechnology industry, including topics such as deal types, partnering contracts, and company sales; best practices in deal preparation; and case studies on common pitfalls and challenges.

According to its website, TAP brings together decision makers to assess the most promising drug programs available for partnering in neuroscience, inflammatory/autoimmune, oncology, cardiovascular/metabolic, infectious diseases, and advanced therapies (including regenerative medicine, rare diseases, gene therapy, cell therapy and other high-value and niche areas). Respected independent experts rigorously review projects available for partnering and select the top 10 projects in each therapeutic area based on the likelihood of their success as future products. Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders.

Elowe concentrates his practice on international business and complex commercial transactions, with an emphasis on mergers and acquisitions, joint ventures, strategic alliances, licensing, and technology transactions. In the life sciences sector, Elowe has represented pharmaceutical companies, biotechnology companies, clinical research organizations and other industry players in transactions ranging from large licensing, development and commercialization deals involving the development of new technologies to joint ventures in China to establish clinical research platforms. He has represented clients doing business in over 50 countries across Europe, Asia, Latin America and the Middle East, and has over 20 years representing companies doing business in China.

Dykeman, who co-chairs the firm's global Life Sciences & Medical Technology group, is a registered patent attorney with over eighteen years of experience in patent and intellectual property law. Dykeman focuses his practice on securing worldwide intellectual property protection and related business strategy for high tech clients, with particular experience in life sciences, biotechnology, medical devices, nanotechnology, and information technology.